- EGFR Signaling Pathway
- TGF-beta Signaling
- Canonical Wnt Signaling
- non-Canonical Wnt Signaling
- Notch Signaling
- p53 Pathway
- NF-kB Pathway
- Cytokine Signaling
>Rabbit PAb Antibody
>Syndecan-1 / SDC1 / CD138 Antibody, Rabbit PAb, Antigen Affinity Purified
|Catalog||Size (Price)||Quantity||In Stock||Operation|
Syndecan-1 / SDC1 / CD138 Antibody ( Antigen Affinity Purified ) Datasheet
|Order or Inquire for Syndecan-1 / SDC1 / CD138 Antibody product||Quality antibodies||Antibody production services|
Syndecan-1 / SDC1 / CD138 Antibody Product Information
Recombinant Human Syndecan-1 / SDC1 / CD138 protein (Catalog#11429-H08H)
|Antibody Type :||Rabbit Polyclonal Antibody ( Antibody Purification Platform )|
|Ig Type :||
|Formulation :||0.2 μm filtered solution in PBS, 5% trehalose may be added in some batches. Please read the hardcopy of COA or contact our customer service to confirm the formulation.|
Produced in rabbits immunized with purified, recombinant Human Syndecan-1 / SDC1 / CD138 (rh Syndecan-1 / SDC1 / CD138; Catalog#11429-H08H; NP_002988.3; Met 1-Glu 251). Syndecan-1 / SDC1 / CD138 specific IgG was purified by Human Syndecan-1 / SDC1 / CD138 affinity chromatography.
Syndecan-1 / SDC1 / CD138 Antibody Usage Guide
Human Syndecan-1 / SDC1 / CD138
IHC-P: 0.1-2 μg/mL
|Western blot :||
WB: 2-5 μg/mL
|Storage :||This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Syndecan-1 / SDC1 / CD138 Antibody Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Syndecan-1/SDC1/CD138||Human||Syndecan-1/SDC1/CD138 Protein, Recombinant||11429-H08H|
|Syndecan-1/SDC1/CD138||Mouse||Syndecan-1/SDC1/CD138 Protein, Recombinant||50641-M08H|
|Syndecan-1/SDC1||Rat||SDC1 / Syndecan-1 / SYND1 Protein, Recombinant||80344-R02H|
|Syndecan-1/SDC1||Rat||SDC1 / Syndecan-1 / SYND1 Protein, Recombinant||80344-R08H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Human Syndecan-1 / SDC1 / CD138||IHC-P||Syndecan-1 / SDC1 / CD138 Antibody (Antigen Affinity Purified)||11429-RP02|
|Mouse Syndecan-1 / SDC1 / CD138||WB, ELISA||Syndecan-1 / SDC1 / CD138 Antibody (Antigen Affinity Purified)||50641-RP02|
Syndecan-1 / SDC1 / CD138 Antibody Background
Syndecan-1, also known as SYND1, CD138 and SDC1, is a single-pass type I membrane protein which belongs to thesyndecan proteoglycan family. CD138 / Syndecan-1, is well known to be associated with cell proliferation, adhesion, and migration in various types of malignancies. CD138 / Syndecan-1 is a cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix. It is a cell-surface heparan sulfate proteoglycan expressed on most epithelial cells, and decreased CD138 expression is associated with increased invasive and metastatic potential in carcinomas. Within the hematopoietic system, CD138 is an excellent marker of plasmacytic differentiation. CD138 / Syndecan-1 is a cell surface proteoglycan that binds cells to the extracellular matrix and its expression is down-regulated in many cellular transformation models. CD138 / Syndecan-1 is a new simple non-invasive marker for predicting liver fibrosis in patients with chronic hepatitis C. The relevance of this marker in combination with other fibrosis markers should be explored. CD138 / Syndecan-1 might contribute to urothelial carcinoma cell survival and progression. It could be a new therapeutic target in human urinary bladder cancer.
- O'Connell, FP. et al., Am J Clin Pathol2004, 121 (2):254-63.
- Gokden,N.et al., 2006, Appl Immunohistochem Mol Morphol. 14 (2): 173-7.
- Sun,WP. et al., 2007, Cell Mol Immunol. 4 (3): 209-14.
- Zvibel, I. et al., 2009, Liver Int. 29 (2): 208-12.
- Shimada,K. et al., 2010, Cancer Sci. 101 (1): 155-60.